Innovent Biologics, Inc. (1801.HK) Bundle
Founded in 2011, Innovent Biologics, Inc. has fast-tracked from a bold startup to a global biopharma force driven by a clear mission-to empower patients worldwide with affordable, high-quality biopharmaceuticals-and a vision to become a premier global biopharmaceutical company, backed by tangible milestones: state-of-the-art manufacturing in Suzhou and Hangzhou with a combined capacity of 140,000 liters (expanding to 230,000 liters), 100% GMP-certified facilities and a 100% batch success rate, over 30 strategic collaborations with partners like Eli Lilly, Roche and Sanofi, patient assistance reaching more than 200,000 patients and donated medicines valued at RMB 3.6 billion in 2024, a 50.6% year-on-year revenue surge the same year, and concrete targets-RMB 20 billion in product revenue by 2027 and five pipeline programs into global Phase 3 by 2030-anchored by core values of Integrity, Learning Agility, Dedication, and Cooperation that steer its R&D, partnerships and sustainability initiatives.
Innovent Biologics, Inc. (1801.HK) Intro
Innovent Biologics, Inc. (1801.HK) is a leading global biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing high‑quality, affordable biologics. Since its founding in 2011, Innovent has built a diversified clinical and commercial portfolio across oncology, autoimmune, cardiovascular, metabolic, and ophthalmology indications, supported by strategic global partnerships and vertically integrated manufacturing capabilities.- Founded: 2011
- Therapeutic focus: Oncology, autoimmune, cardiovascular, metabolic, ophthalmology
- Manufacturing sites: Suzhou and Hangzhou
- Strategic partnerships: >30 collaborations with international biopharma (including Eli Lilly, Roche, Sanofi)
- ESG reporting: 2024 ESG report highlighting environmental responsibility and global innovation
| Category | Detail |
|---|---|
| Registered ticker | 1801.HK |
| Established | 2011 |
| Manufacturing capacity (current) | 140,000 liters (combined Suzhou & Hangzhou) |
| Planned manufacturing capacity | 230,000 liters |
| GMP certification | 100% of production facilities GMP‑certified |
| Batch success rate | 100% in drug substance manufacturing |
| Strategic collaborations | Over 30 global partners (incl. Eli Lilly, Roche, Sanofi) |
| Key therapeutic areas | Oncology, autoimmune, cardiovascular, metabolic, ophthalmology |
- Deliver accessible, high‑quality biopharmaceuticals to patients worldwide through rigorous R&D, scalable manufacturing, and ethical commercialization.
- Advance science through partnerships and internal innovation to bring transformative therapies to market efficiently and affordably.
- Be a globally trusted leader in biopharmaceutical innovation, recognized for translating breakthrough science into patient‑centric, affordable therapies.
- Scale sustainable biomanufacturing to meet global unmet medical needs while maintaining high quality and safety standards.
- Patient Centricity - prioritize patient outcomes and access in decision‑making.
- Scientific Rigor - uphold high standards in discovery, development, and manufacturing (100% GMP, 100% batch success in drug substance).
- Collaboration - pursue strategic alliances to accelerate innovation and broaden global reach (30+ partnerships).
- Integrity & Quality - ensure compliance, transparency, and reproducibility across operations.
- Sustainability - integrate environmental and social responsibility, as reflected in the 2024 ESG report.
- Vertical integration: in‑house discovery through commercial manufacturing across Suzhou and Hangzhou sites.
- Scale‑up roadmap: expanding production from 140,000 L to 230,000 L to support late‑stage clinical growth and commercial supply.
- Partner ecosystem: collaborations with multinational pharmas to co‑develop and commercialize assets globally.
- Quality metrics: company‑reported 100% GMP coverage and 100% batch success in drug substance manufacturing, underpinning supply reliability.
Innovent Biologics, Inc. (1801.HK) - Overview
Innovent Biologics, Inc. (1801.HK) centers its corporate purpose on a clear mission: to empower patients worldwide with affordable, high-quality biopharmaceuticals. This mission drives strategy across R&D, commercialization, patient access and partnerships, directing resources toward making advanced biologics reachable for diverse patient populations and addressing unmet medical needs.- Patient access commitment: in 2024 Innovent's patient assistance programs benefited over 200,000 patients, with donated medicines valued at more than RMB 3.6 billion.
- Affordability focus: pricing and access programs designed to reduce financial barriers and expand treatment uptake across domestic and international markets.
- R&D alignment: pipeline prioritization targets high-unmet-need oncology, immunology and ophthalmology indications to translate innovative science into practical treatments.
- Global reach: strategic partnerships and licensing seek to scale distribution while preserving affordability commitments.
| Metric | Value / Note |
|---|---|
| Mission statement | 'To empower patients worldwide with affordable, high-quality biopharmaceuticals.' |
| Patients supported (2024) | Over 200,000 |
| Value of donated medicines (2024) | More than RMB 3.6 billion |
| Core therapeutic focus | Oncology, immunology, ophthalmology and other biologics-driven areas |
| Representative marketed products | Sintilimab (Tyvyt) and multiple biosimilars and biologic assets developed in-house |
- How mission shapes operations:
- Clinical development portfolios prioritize scalable biologics and indications with large population impact.
- Commercial strategies pair price-access programs with channel expansion to broaden reach without compromising quality.
- Partnerships and alliances are evaluated for both scientific fit and potential to extend affordable access globally.
Innovent Biologics, Inc. (1801.HK) - Mission Statement
Innovent Biologics, Inc. (1801.HK) centers its mission on developing high-quality, accessible biologics that address unmet medical needs and improve patient outcomes worldwide. This mission is driven by a commitment to scientific rigor, scalable manufacturing, strategic global partnerships, and measurable commercial performance. Vision Statement Innovent's vision is 'to be a premier global biopharmaceutical company.' That vision informs strategy across R&D, manufacturing, commercialization, and international collaboration, and is reflected in measurable progress and forward-looking targets.- 2024 performance: total revenue increased 50.6% year-on-year, signalling accelerated commercial traction and operational scale-up.
- Mid-term revenue target: achieve RMB 20 billion in product revenue by 2027.
- Clinical pipeline ambition: advance five pipeline programs into global Phase 3 trials by 2030.
- Globalization: expanding partnerships and registrations to broaden patient access beyond China.
- Quality & innovation: continual investment in biologics R&D, CMC capabilities, and regulatory excellence.
| Category | Metric / Target | Timeline | 2024 Status |
|---|---|---|---|
| Revenue Growth | 50.6% year-on-year increase | Reported 2024 | Total revenue up 50.6% YoY |
| Product Revenue Target | RMB 20 billion | By 2027 | On trajectory via commercial expansion |
| Clinical Pipeline | Advance 5 programs to global Phase 3 | By 2030 | Multiple assets in global trials and earlier phases |
| Global Partnerships | Strategic collaborations with international organizations | Ongoing | Partnerships expanding global reach and access |
| Quality & Manufacturing | Enhance CMC capacity and regulatory filings | Continuous | Investment in GMP facilities and tech transfer |
- Patient-centricity: prioritize patient outcomes and access in portfolio decisions.
- Scientific excellence: rigorous translational science and evidence generation.
- Operational discipline: scale manufacturing and commercialization efficiently.
- Collaborative mindset: pursue global partnerships to accelerate development and distribution.
- Integrity & compliance: maintain high regulatory and ethical standards.
Innovent Biologics, Inc. (1801.HK) - Vision Statement
Innovent Biologics envisions becoming a globally recognized biopharmaceutical pioneer that delivers differentiated, high-quality biologic therapies to patients worldwide. Grounded in a mission to translate cutting-edge science into accessible medicines, Innovent aims to expand therapeutic options across oncology, autoimmune, metabolic and ophthalmic diseases while driving innovation through strategic partnerships and relentless R&D investment.- Integrity: Upholding ethical practices, regulatory compliance, and transparency to build trust with patients, physicians, regulators, and investors.
- Learning Agility: Continuously integrating new scientific insights, platform technologies, and real-world evidence to accelerate development timelines.
- Dedication: Committing resources and talent to advance life-changing therapeutics and improve patient outcomes globally.
- Cooperation: Leveraging internal cross-functional collaboration and external alliances with global pharma, academic centers, and contract partners to scale impact.
| Metric | Reported / Estimated Value |
|---|---|
| Founded | 2011 |
| Hong Kong listing (Ticker: 1801.HK) | 2018 IPO |
| Employees (approx.) | ~3,500-4,000 |
| Commercialized products (marketed biologics) | 6+ (including PD‑1 and multiple antibodies and biosimilars) |
| Clinical-stage pipeline | 20-30 assets across phases I-III |
| Annual R&D investment (most recent reported year) | RMB billions (significant multi-year growth reflecting dedication to innovation) |
| Global partnerships & licensing deals | Multiple high-profile alliances with multinational pharma and regional partners |
- Advance proprietary biologics from discovery through global registration while maintaining rigorous compliance and ethical standards.
- Sustain high R&D intensity-allocating a significant portion of revenue to discovery platforms, translational science, and clinical development.
- Scale manufacturing capabilities to ensure supply reliability and affordability for patients, reflecting dedication and integrity.
- Expand external collaborations to accelerate market access and broaden therapeutic reach, embodying cooperation and learning agility.
Innovent Biologics, Inc. (1801.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.